跳转至内容
Merck
CN

L6292

Sigma-Aldrich

赖诺普利

≥98% (HPLC)

别名:

MK-521, (S)-1- [N2-(1-羧基-3-苯丙基)-赖氨酰脯氨酸 二水合物

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H31O5N3 · 2H2O
CAS号:
分子量:
441.52
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.32

质量水平

检测方案

≥98% (HPLC)

形式

solid

颜色

white

溶解性

H2O: ≥10 mg/mL
DMSO: ~6.5 mg/mL (with heating and sonicating)

储存温度

2-8°C

SMILES字符串

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

InChI key

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

基因信息

human ... ACE(1636)

正在寻找类似产品? 访问 产品对比指南

相关类别

应用

赖诺普利已被用于研究杜氏营养不良症小鼠的抗纤维化作用。它已被用于研究经过长期达贝泊汀处理后的 TGR(mRen2)27 (携带小鼠 Ren-2 基因的转基因大鼠)大鼠的肾结构和功能的变化。

生化/生理作用

血管紧张素转换酶(ACE)抑制剂。

特点和优势

该化合物是位于美国新泽西Kenilworth的Merck & Co., Inc.开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单, 请单击此处

象形图

Health hazard

警示用语:

Danger

危险声明

危险分类

Repr. 1A - STOT RE 2

靶器官

Kidney

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Anne-Roos S Frenay et al.
Journal of the renin-angiotensin-aldosterone system : JRAAS, 13(2), 232-238 (2012-01-28)
Erytropoietin (EPO) has cytoprotective and angiogenic properties and has a beneficial effect in ischaemic conditions. Since the development of renal interstitial abnormalities are often associated with ischaemia, we studied the effects of the long-acting EPO analogue darbepoetin alpha (DA) on
Jason V Baker et al.
PloS one, 7(10), e46894-e46894 (2012-10-20)
Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed. We conducted a 2 × 2 factorial feasibility study of lisinopril (L) (10 mg daily) vs L-placebo in combination
Saleh Yazdani et al.
PloS one, 7(11), e50209-e50209 (2012-11-29)
Proteinuria is an important cause of progressive tubulo-interstitial damage. Whether proteinuria could trigger a renal lymphangiogenic response has not been established. Moreover, the temporal relationship between development of fibrosis, inflammation and lymphangiogenesis in chronic progressive kidney disease is not clear
Nadir Ulu et al.
The Journal of pharmacology and experimental therapeutics, 345(3), 393-403 (2013-03-27)
Transactivation of epidermal growth factor receptor (EGFR) signaling by G protein-coupled receptors has been implicated in several cardiovascular (CV) conditions, including hypertension, heart failure, and cardiac and vascular hypertrophy. However, the therapeutic potential of EGFR inhibition in these conditions is
Tatjana Ignjatovic et al.
The Journal of biological chemistry, 277(19), 16847-16852 (2002-03-07)
Angiotensin I converting enzyme (kininase II; ACE) inhibitors are important therapeutic agents widely used for treatment in cardiovascular and renal diseases. They inhibit angiotensin II release and bradykinin inactivation; these actions do not explain completely the clinical benefits. We found

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门